GlassScriptPhysician profile
Sharon C Upton
NPI 1851408744
$9,940.22
in general payments reported to CMS, 2019-2025
41 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,834 · 2022: $1,994 · 2023: $2,117 · 2024: $1,937 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,022 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,022.30 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,421.88 | 2021-2025 | |
| Lilly USA, LLC | $941.79 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $929.85 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $773.00 | 2021-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $720.50 | 2022-2025 | |
| Pfizer INC. | $662.63 | 2021-2025 | |
| Amgen INC. | $638.55 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $467.67 | 2021-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $406.71 | 2021-2025 | Spravato |
| Daiichi Sankyo INC. | $390.30 | 2021-2025 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $273.97 | 2023-2025 | Rexulti |
| Dexcom, INC. | $271.32 | 2021-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $269.76 | 2021-2025 | Veozah, Myrbetriq |
| Ironwood Pharmaceuticals, INC | $257.60 | 2021-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.10 | 2021-2025 | Xifaxan, Trulance |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $206.01 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $123.52 | 2023-2024 | Gemtesa |
| Lundbeck LLC | $113.65 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $97.24 | 2021 | |
| Sunovion Pharmaceuticals INC. | $95.03 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $89.26 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Phathom Pharmaceuticals, INC. | $72.67 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $60.79 | 2024-2025 | Nexletol |
| Averitas Pharma INC. | $58.52 | 2023 | Qutenza |
| Novartis Pharmaceuticals Corporation | $56.89 | 2022-2023 | |
| Corcept Therapeutics | $54.35 | 2024-2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $31.55 | 2021-2023 | Eliquis |
| Seqirus USA INC | $30.15 | 2022-2024 | Flucelvax, Fluad |
| Bausch Health US, LLC | $28.45 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.89 | 2025 | Recorlev |
| Boston Scientific Corporation | $20.35 | 2024 | Watchman Flx |
| Antares Pharma, INC. | $17.90 | 2025 | Xyosted |
| Lexicon Pharmaceuticals, INC. | $17.57 | 2023 | Inpefa |
| Electromed, INC. | $17.27 | 2025 | Smartvest |
| Nestle Healthcare Nutrition INC. | $15.46 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.01 | 2021 | |
| Shield Therapeutics INC | $13.63 | 2023 | Accrufer |
| Acella Pharmaceuticals, LLC | $13.53 | 2023 | NP Thyroid 60 |
| Idorsia Pharmaceuticals US INC | $12.59 | 2022 | |
| Corium, LLC | $12.41 | 2022 | |
| Exeltis, USA INC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Upton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.